Open AccessInvasive Ductal Carcinoma Breast: How Neoadjuvant Chemotherapy Affects the Status of Estrogen Receptor, Progesterone Receptor and HER2/Neu- A Tertiary Care Centre Study
Author(s) -
Swasti Shubham,
Pratibha Maan,
Monika Singh,
Minakshi Bhardwaj
Publication year - 2017
Publication title -
journal of clinical and diagnostic research
Language(s) - English
Resource type - Journals
eISSN - 2249-782X
pISSN - 0973-709X
DOI - 10.7860/jcdr/2017/29063.10201
Subject(s) - medicine , progesterone receptor , estrogen receptor , oncology , immunohistochemistry , breast cancer , her2/neu , mcnemar's test , ductal carcinoma , breast carcinoma , gynecology , cancer , statistics , mathematics
Determination of Estrogen Receptor (ER), Progesterone Receptor (PR) and HER2/neu in primary Invasive Ductal Carcinoma (IDC) breast is the standard of care parameter for determining treatment options. Whether or not Neoadjuvant Chemotherapy (NAC) affects the receptor status is still an unanswered question.